Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identification of Small Molecules as Zika Virus Entry Inhibitors.

International journal of molecular sciences·2025

Same author

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients.

International journal of molecular sciences·2025

Same author

Envelope Protein-Targeting Zika Virus Entry Inhibitors.

International journal of molecular sciences·2024

Same author

Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors.

Viruses·2023

Same author

Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.

International journal of molecular sciences·2022

Same author

Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse Model.

Viruses·2022

Same journal

Exploration of a Novel Physicochemical Property Space for the Development of Antimalarial Drugs.

Current topics in medicinal chemistry·2026

Same journal

Computational Drug Design of Natural Product-Based Azole Hybrids for Multifactorial Diseases: Success Stories.

Current topics in medicinal chemistry·2026

Same journal

Simulated Natural Nanoparticles in Bai-Hu-Tang Decoction: Preparation, Characterization, Pharmacokinetics, and Antipyretic Effects.

Current topics in medicinal chemistry·2026

Same journal

Dolabellane Diterpenes from the Marine Brown Alga Dictyota dolabellana and their Potential Antiviral Activity.

Current topics in medicinal chemistry·2026

Same journal

Inhibitory Effects of Flavonoids from the Stems and Leaves of Scutellaria baicalensis Georgi on Oligodendrocyte Pyroptosis Induced by Aβ1-42.

Current topics in medicinal chemistry·2026

Same journal

Mechanism of Huangqishihu Decoction in Treating Liver Fibrosis in Rats Model via Regulation of Oxidative Stress and Nrf2 Signaling Pathway.

Current topics in medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 4, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Lu Lu, Fei Yu, Lifeng Cai

¹Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Building #13, Shanghai 200032, China. shibojiang@fudan.edu.cn.

Current Topics in Medicinal Chemistry

|September 2, 2015

Summary

This summary is machine-generated.

Developing small-molecule inhibitors targeting HIV-1 envelope glycoproteins gp120 and gp41 is crucial for advancing HIV entry inhibitor therapies beyond peptide-based drugs like enfuvirtide.

More Related Videos

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

Related Experiment Videos

Last Updated: Apr 4, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

Area of Science:

Virology
Drug Discovery
Immunology

Background:

Human immunodeficiency virus type 1 (HIV-1) entry relies on envelope glycoproteins gp120 and gp41.
Current entry inhibitors, like enfuvirtide, face limitations such as lack of oral availability.
Targeting these glycoproteins is essential for developing new HIV therapies.

Purpose of the Study:

To review the structure and function of HIV-1 gp120 and gp41.
To survey advancements in small-molecule HIV entry inhibitors targeting these glycoproteins.
To compare different classes of HIV entry inhibitor candidates and predict future trends.

Main Methods:

Literature review of HIV-1 Env glycoprotein structure and function.
Analysis of recent developments in small-molecule HIV entry inhibitors.
Comparative assessment of various inhibitor categories and their clinical potential.

Main Results:

Detailed description of gp120 and gp41 roles in HIV-1 entry.
Overview of emerging small-molecule inhibitors targeting HIV-1 Env.
Comparison of advantages and disadvantages of different inhibitor strategies.

Conclusions:

Small-molecule inhibitors targeting gp120 and gp41 represent a promising avenue for next-generation HIV entry inhibitors.
Overcoming limitations of current therapies requires innovative drug design and development.
Future research should focus on optimizing oral bioavailability and efficacy of novel HIV entry inhibitors.